ViaLongeVita

From the Czech desk of MedScopeGlobal. Shared with attribution — the local desk added context for this edition.

Atezolizumab in early triple-negative breast cancer: the randomized phase 3 NSABP B-59/GeparDouze trialVIP

Nature Medicine, Published online: 01 September 2026; doi:10.1038/s41591-026-04565-6 The phase 3 NSABP B-59/GeparDouze trial, in which patients with early-stage triple-negative breast cancer received neoadjuvant chemotherapy with or without atezolizumab, did not meet its primary endpoint of event-free survival, and com

Este conteúdo não é diagnóstico médico nem recomendação de tratamento. Consulte sempre o seu médico ou o SUS.